CD81-receptor associations - Impact for hepatitis C virus entry and antiviral therapies

Viruses

Volumn 6, Issue 2, 2014, Pages 875-892

  Zona, Laetitia ^a,b   Tawar, Rajiv G ^a,b   Zeisel, Mirjam B ^a,b   Xiao, Fei ^a,b   Schuster, Catherine ^a,b   Lupberger, Joachim ^a,b   Baumert, Thomas F ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Antivirals; Claudin 1; Kinases; Liver; Transplantation

Indexed keywords

BETA1 INTEGRIN; CD151 ANTIGEN; CD19 ANTIGEN; CD53 ANTIGEN; CD63 ANTIGEN; CD71 ANTIGEN; CD81 ANTIGEN RECEPTOR; CD82 ANTIGEN; CD9 ANTIGEN; CLAUDIN 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLYCOPROTEIN E2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; LYMPHOCYTE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD81; OCCLUDIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRE B CELL RECEPTOR; PROTEIN CDC42; PROTEIN KINASE C; PROTEIN TYROSINE PHOSPHATASE SHP; RHO KINASE; SCAVENGER RECEPTOR BI; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANTIVIRAL THERAPY; CELL ADHESION; CELL MOTILITY; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; VIRUS ENTRY; VIRUS REPLICATION;

ANTIGENS, CD81; HEPACIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, VIRUS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84893943976     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6020875     Document Type: Review

References (107)

1. Oren, R.; Takahashi, S.; Doss, C.; Levy, R.; Levy, S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol. Cell. Biol. 1990, 10, 4007-4015.
2. Levy, S.; Shoham, T. The tetraspanin web modulates immune-signalling complexes. Nat. Rev. Immunol. 2005, 5, 136-148.
3. Boucheix, C.; Rubinstein, E. Tetraspanins. Cell. Mol. Life Sci. 2001, 58, 1189-1205.
4. Charrin, S.; Manie, S.; Oualid, M.; Billard, M.; Boucheix, C.; Rubinstein, E. Differential stability of tetraspanin/tetraspanin interactions: Role of palmitoylation. FEBS Lett. 2002, 516, 139-144.
5. Charrin, S.; Manie, S.; Thiele, C.; Billard, M.; Gerlier, D.; Boucheix, C.; Rubinstein, E. A physical and functional link between cholesterol and tetraspanins. Eur. J. Immunol. 2003, 33, 2479-2489.
6. Berditchevski, F.; Odintsova, E.; Sawada, S.; Gilbert, E. Expression of the palmitoylation-deficient CD151 weakens the association of alpha 3 beta 1 integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling. J. Biol. Chem. 2002, 277, 36991-37000.
7. Yang, X.; Claas, C.; Kraeft, S.K.; Chen, L.B.; Wang, Z.; Kreidberg, J.A.; Hemler, M.E. Palmitoylation of tetraspanin proteins: Modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Mol. Biol. Cell 2002, 13, 767-781.
8. Claas, C.; Stipp, C.S.; Hemler, M.E. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J. Biol. Chem. 2001, 276, 7974-7984.
9. Hemler, M.E. Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol. 2005, 6, 801-811.
10. Le Naour, F.; Andre, M.; Boucheix, C.; Rubinstein, E. Membrane microdomains and proteomics: Lessons from tetraspanin microdomains and comparison with lipid rafts. Proteomics 2006, 6, 6447-6454.
11. Hemler, M.E. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu. Rev. Cell Dev. Biol. 2003, 19, 397-422.
12. Martin, F.; Roth, D.M.; Jans, D.A.; Pouton, C.W.; Partridge, L.J.; Monk, P.N.; Moseley, G.W. Tetraspanins in viral infections: A fundamental role in viral biology? J. Virol. 2005, 79, 10839-10851.
13. Perrault, M.; Pecheur, E.I. The hepatitis C virus and its hepatic environment: A toxic but finely tuned partnership. Biochem. J. 2009, 423, 303-314.
14. Kovalenko, O.V.; Yang, X.; Kolesnikova, T.V.; Hemler, M.E. Evidence for specific tetraspanin homodimers: Inhibition of palmitoylation makes cysteine residues available for cross-linking. Biochem. J. 2004, 377, 407-417.
15. Serru, V.; Le Naour, F.; Billard, M.; Azorsa, D.O.; Lanza, F.; Boucheix, C.; Rubinstein, E. Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem. J. 1999, 340, 103-111.
16. Charrin, S.; Le Naour, F.; Labas, V.; Billard, M.; Le Caer, J.P.; Emile, J.F.; Petit, M.A.; Boucheix, C.; Rubinstein, E. EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells. Biochem. J. 2003, 373, 409-421.
17. Zhang, X.A.; Lane, W.S.; Charrin, S.; Rubinstein, E.; Liu, L. EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells. Canc. Res. 2003, 63, 2665-2674.
18. Sala-Valdes, M.; Ursa, A.; Charrin, S.; Rubinstein, E.; Hemler, M.E.; Sanchez-Madrid, F.; Yanez-Mo, M. EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins. J. Biol. Chem. 2006, 281, 19665-19675.
19. Berditchevski, F. Complexes of tetraspanins with integrins: More than meets the eye. J. Cell Sci. 2001, 114, 4143-4151.
20. Miyazaki, T.; Muller, U.; Campbell, K.S. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J. 1997, 16, 4217-4225.
21. Tsitsikov, E.N.; Gutierrez-Ramos, J.C.; Geha, R.S. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc. Natl. Acad. Sci. USA 1997, 94, 10844-10849.
22. Maecker, H.T.; Levy, S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J. Exp. Med. 1997, 185, 1505-1510.
23. van Zelm, M.C.; Smet, J.; Adams, B.; Mascart, F.; Schandene, L.; Janssen, F.; Ferster, A.; Kuo, C.C.; Levy, S.; van Dongen, J.J.; et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J. Clin. Invest. 2010, 120, 1265-1274.
24. Carloni, V.; Mazzocca, A.; Ravichandran, K.S. Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cells. Oncogene 2004, 23, 1566-1574.
25. Zhang, X.A.; Bontrager, A.L.; Hemler, M.E. Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(1) integrins. J. Biol. Chem. 2001, 276, 25005-25013.
26. Silvie, O.; Rubinstein, E.; Franetich, J.F.; Prenant, M.; Belnoue, E.; Renia, L.; Hannoun, L.; Eling, W.; Levy, S.; Boucheix, C.; et al. Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat. Med. 2003, 9, 93-96.
27. Yalaoui, S.; Zougbede, S.; Charrin, S.; Silvie, O.; Arduise, C.; Farhati, K.; Boucheix, C.; Mazier, D.; Rubinstein, E.; Froissard, P. Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. PLoS Pathog. 2008, 4, e1000010.
28. Tham, T.N.; Gouin, E.; Rubinstein, E.; Boucheix, C.; Cossart, P.; Pizarro-Cerda, J. Tetraspanin CD81 is required for Listeria monocytogenes invasion. Infect. Immun. 2010, 78, 204-209.
29. Pileri, P.; Uematsu, Y.; Campagnoli, S.; Galli, G.; Falugi, F.; Petracca, R.; Weiner, A.J.; Houghton, M.; Rosa, D.; Grandi, G.; et al. Binding of hepatitis C virus to CD81. Science 1998, 282, 938-941.
30. Cormier, E.G.; Tsamis, F.; Kajumo, F.; Durso, R.J.; Gardner, J.P.; Dragic, T. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. USA 2004, 101, 7270-7274.
31. Zhang, J.; Randall, G.; Higginbottom, A.; Monk, P.; Rice, C.M.; McKeating, J.A. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 2004, 78, 1448-1455.
32. Gordon-Alonso, M.; Yanez-Mo, M.; Barreiro, O.; Alvarez, S.; Munoz-Fernandez, M.A.; Valenzuela-Fernandez, A.; Sanchez-Madrid, F. Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion. J. Immunol. 2006, 177, 5129-5137.
33. Alter, M.J. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 2007, 13, 2436-2441.
34. El-Serag, H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142, 1264-1273.
35. Arzumanyan, A.; Reis, H.M.; Feitelson, M.A. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat. Rev. Canc. 2013, 13, 123-135.
36. Marsh, M.; Helenius, A. Virus entry: Open sesame. Cell 2006, 124, 729-740.
37. Timpe, J.M.; Stamataki, Z.; Jennings, A.; Hu, K.; Farquhar, M.J.; Harris, H.J.; Schwarz, A.; Desombere, I.; Roels, G.L.; Balfe, P.; et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008, 47, 17-24.
38. Brimacombe, C.L.; Grove, J.; Meredith, L.W.; Hu, K.; Syder, A.J.; Flores, M.V.; Timpe, J.M.; Krieger, S.E.; Baumert, T.F.; Tellinghuisen, T.L.; et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 2011, 85, 596-605.
39. Schwarz, A.K.; Grove, J.; Hu, K.; Mee, C.J.; Balfe, P.; McKeating, J.A. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J. Virol. 2009, 83, 12407-12414.
40. Fofana, I.; Fafi-Kremer, S.; Carolla, P.; Fauvelle, C.; Zahid, M.N.; Turek, M.; Heydmann, L.; Cury, K.; Hayer, J.; Combet, C.; et al. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 2012, 143, 223-233 e229.
41. Lupberger, J.; Zeisel, M.B.; Xiao, F.; Thumann, C.; Fofana, I.; Zona, L.; Davis, C.; Mee, C.J.; Turek, M.; Gorke, S.; et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 2011, 17, 589-595.
42. Zona, L.; Lupberger, J.; Sidahmed-Adrar, N.; Thumann, C.; Harris, H.J.; Barnes, A.; Florentin, J.; Tawar, R.G.; Xiao, F.; Turek, M.; et al. HRas Signal Transduction Promotes Hepatitis C Virus Cell Entry by Triggering Assembly of the Host Tetraspanin Receptor Complex. Cell Host Microbe 2013, 13, 302-313.
43. Hsu, M.; Zhang, J.; Flint, M.; Logvinoff, C.; Cheng-Mayer, C.; Rice, C.M.; McKeating, J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. USA 2003, 100, 7271-7276.
44. Steinmann, E.; Penin, F.; Kallis, S.; Patel, A.H.; Bartenschlager, R.; Pietschmann, T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 2007, 3, e103.
45. Jirasko, V.; Montserret, R.; Appel, N.; Janvier, A.; Eustachi, L.; Brohm, C.; Steinmann, E.; Pietschmann, T.; Penin, F.; Bartenschlager, R. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. J. Biol. Chem. 2008, 283, 28546-28562.
46. Jones, D.M.; Patel, A.H.; Targett-Adams, P.; McLauchlan, J. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J. Virol. 2009, 83, 2163-2177.
47. Ma, Y.; Yates, J.; Liang, Y.; Lemon, S.M.; Yi, M. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J. Virol. 2008, 82, 7624-7639.
48. Gastaminza, P.; Cheng, G.; Wieland, S.; Zhong, J.; Liao, W.; Chisari, F.V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008, 82, 2120-2129.
49. Huang, H.; Sun, F.; Owen, D.M.; Li, W.; Chen, Y.; Gale, M., Jr.; Ye, J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. USA 2007, 104, 5848-5853.
50. Benga, W.J.; Krieger, S.E.; Dimitrova, M.; Zeisel, M.B.; Parnot, M.; Lupberger, J.; Hildt, E.; Luo, G.; McLauchlan, J.; Baumert, T.F.; et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 2010, 51, 43-53.
51. Bartosch, B.; Dubuisson, J.; Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197, 633-642.
52. Bartosch, B.; Vitelli, A.; Granier, C.; Goujon, C.; Dubuisson, J.; Pascale, S.; Scarselli, E.; Cortese, R.; Nicosia, A.; Cosset, F.L. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 2003, 278, 41624-41630.
53. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Krausslich, H.G.; Mizokami, M.; et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791-796.
54. Zhong, J.; Gastaminza, P.; Cheng, G.; Kapadia, S.; Kato, T.; Burton, D.R.; Wieland, S.F.; Uprichard, S.L.; Wakita, T.; Chisari, F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2005, 102, 9294-9299.
55. Lavillette, D.; Tarr, A.W.; Voisset, C.; Donot, P.; Bartosch, B.; Bain, C.; Patel, A.H.; Dubuisson, J.; Ball, J.K.; Cosset, F.L. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005, 41, 265-274.
56. Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wolk, B.; Tellinghuisen, T.L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A.; et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623-626.
57. McKeating, J.A.; Zhang, L.Q.; Logvinoff, C.; Flint, M.; Zhang, J.; Yu, J.; Butera, D.; Ho, D.D.; Dustin, L.B.; Rice, C.M.; Balfe, P. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J. Virol. 2004, 78, 8496-8505.
58. Mee, C.J.; Harris, H.J.; Farquhar, M.J.; Wilson, G.; Reynolds, G.; Davis, C.; van, I.S.C.; Balfe, P.; McKeating, J.A. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J. Virol. 2009, 83, 6211-6221.
59. Koutsoudakis, G.; Herrmann, E.; Kallis, S.; Bartenschlager, R.; Pietschmann, T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 2007, 81, 588-598.
60. Akazawa, D.; Date, T.; Morikawa, K.; Murayama, A.; Miyamoto, M.; Kaga, M.; Barth, H.; Baumert, T.F.; Dubuisson, J.; Wakita, T. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol. 2007, 81, 5036-5045.
61. Zhang, Y.Y.; Zhang, B.H.; Ishii, K.; Liang, T.J. Novel function of CD81 in controlling hepatitis C virus replication. J. Virol. 2010, 84, 3396-3407.
62. Flint, M.; Maidens, C.; Loomis-Price, L.D.; Shotton, C.; Dubuisson, J.; Monk, P.; Higginbottom, A.; Levy, S.; McKeating, J.A. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 1999, 73, 6235-6244.
63. Petracca, R.; Falugi, F.; Galli, G.; Norais, N.; Rosa, D.; Campagnoli, S.; Burgio, V.; Di Stasio, E.; Giardina, B.; Houghton, M.; et al. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J. Virol. 2000, 74, 4824-4830.
64. Drummer, H.E.; Wilson, K.A.; Poumbourios, P. Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J. Virol. 2002, 76, 11143-11147.
65. Masciopinto, F.; Campagnoli, S.; Abrignani, S.; Uematsu, Y.; Pileri, P. The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor. Virus Res. 2001, 80, 1-10.
66. Bertaux, C.; Dragic, T. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J. Virol. 2006, 80, 4940-4948.
67. Voisset, C.; Lavie, M.; Helle, F.; Op De Beeck, A.; Bilheu, A.; Bertrand-Michel, J.; Terce, F.; Cocquerel, L.; Wychowski, C.; Vu-Dac, N.; et al. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. Cell. Microbiol. 2008, 10, 606-617.
68. Kapadia, S.B.; Barth, H.; Baumert, T.; McKeating, J.A.; Chisari, F.V. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J. Virol. 2007, 81, 374-383.
69. Harris, H.J.; Clerte, C.; Farquhar, M.J.; Goodall, M.; Hu, K.; Rassam, P.; Dosset, P.; Wilson, G.K.; Balfe, P.; Ijzendoorn, S.C.; et al. Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Cell. Microbiol. 2013, 15, 430-445.
70. Farquhar, M.J.; Hu, K.; Harris, H.J.; Davis, C.; Brimacombe, C.L.; Fletcher, S.J.; Baumert, T.F.; Rappoport, J.Z.; Balfe, P.; McKeating, J.A. Hepatitis C virus induces CD81 and claudin-1 endocytosis. J. Virol. 2012, 86, 4305-4316.
71. Flint, M.; von Hahn, T.; Zhang, J.; Farquhar, M.; Jones, C.T.; Balfe, P.; Rice, C.M.; McKeating, J.A. Diverse CD81 proteins support hepatitis C virus infection. J. Virol. 2006, 80, 11331-11342.
72. Higginbottom, A.; Quinn, E.R.; Kuo, C.C.; Flint, M.; Wilson, L.H.; Bianchi, E.; Nicosia, A.; Monk, P.N.; McKeating, J.A.; Levy, S. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J. Virol. 2000, 74, 3642-3649.
73. Davis, C.; Harris, H.J.; Hu, K.; Drummer, H.E.; McKeating, J.A.; Mullins, J.G.; Balfe, P. In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface. Cell. Microbiol. 2012, 14, 1892-1903.
74. Montpellier, C.; Tews, B.A.; Poitrimole, J.; Rocha-Perugini, V.; D'Arienzo, V.; Potel, J.; Zhang, X.A.; Rubinstein, E.; Dubuisson, J.; Cocquerel, L. Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection. J. Biol. Chem. 2011, 286, 13954-13965.
75. Brazzoli, M.; Bianchi, A.; Filippini, S.; Weiner, A.; Zhu, Q.; Pizza, M.; Crotta, S. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 2008, 82, 8316-8329.
76. Mazzocca, A.; Sciammetta, S.C.; Carloni, V.; Cosmi, L.; Annunziato, F.; Harada, T.; Abrignani, S.; Pinzani, M. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J. Biol. Chem. 2005, 280, 11329-11339.
77. Zeisel, M.B.; Felmlee, D.J.; Baumert, T.F. Hepatitis C virus entry. Curr. Top. Microbiol. Immunol. 2013, 369, 87-112.
78. Park, J.H.; Park, S.; Yang, J.S.; Kwon, O.S.; Kim, S.; Jang, S.K. Discovery of cellular proteins required for the early steps of HCV infection using integrative genomics. PLoS One 2013, 8, e60333.
79. Levy, S.; Shoham, T. Protein-protein interactions in the tetraspanin web. Physiology 2005, 20, 218-224.
80. Harris, H.J.; Davis, C.; Mullins, J.G.; Hu, K.; Goodall, M.; Farquhar, M.J.; Mee, C.J.; McCaffrey, K.; Young, S.; Drummer, H.; et al. Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem. 2010, 285, 21092-21102.
81. Harris, H.J.; Farquhar, M.J.; Mee, C.J.; Davis, C.; Reynolds, G.M.; Jennings, A.; Hu, K.; Yuan, F.; Deng, H.; Hubscher, S.G.; et al. CD81 and claudin 1 coreceptor association: Role in hepatitis C virus entry. J. Virol. 2008, 82, 5007-5020.
82. Furuse, M.; Hata, M.; Furuse, K.; Yoshida, Y.; Haratake, A.; Sugitani, Y.; Noda, T.; Kubo, A.; Tsukita, S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice. J. Cell Biol. 2002, 156, 1099-1111.
83. Evans, M.J.; von Hahn, T.; Tscherne, D.M.; Syder, A.J.; Panis, M.; Wolk, B.; Hatziioannou, T.; McKeating, J.A.; Bieniasz, P.D.; Rice, C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446, 801-805.
84. Krieger, S.E.; Zeisel, M.B.; Davis, C.; Thumann, C.; Harris, H.J.; Schnober, E.K.; Mee, C.; Soulier, E.; Royer, C.; Lambotin, M.; et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 2010, 51, 1144-1157.
85. Douam, F.; Dao Thi, V.L.; Maurin, G.; Fresquet, J.; Mompelat, D.; Zeisel, M.B.; Baumert, T.F.; Cosset, F.L.; Lavillette, D. A critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry Hepatology 2013, doi:10.1002/hep.26733.
86. Reynolds, G.M.; Harris, H.J.; Jennings, A.; Hu, K.; Grove, J.; Lalor, P.F.; Adams, D.H.; Balfe, P.; Hubscher, S.G.; McKeating, J.A. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 2008, 47, 418-427.
87. Yang, W.; Qiu, C.; Biswas, N.; Jin, J.; Watkins, S.C.; Montelaro, R.C.; Coyne, C.B.; Wang, T. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J. Biol. Chem. 2008, 283, 8643-8653.
88. Farquhar, M.J.; Harris, H.J.; Diskar, M.; Jones, S.; Mee, C.J.; Nielsen, S.U.; Brimacombe, C.L.; Molina, S.; Toms, G.L.; Maurel, P.; et al. Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J. Virol. 2008, 82, 8797-8811.
89. Liu, Z.; Tian, Y.; Machida, K.; Lai, M.M.; Luo, G.; Foung, S.K.; Ou, J.H. Transient Activation of the PI3K-AKT Pathway by Hepatitis C Virus to Enhance Viral Entry. J. Biol. Chem. 2012, 287, 41922-41930.
90. Diao, J.; Pantua, H.; Ngu, H.; Komuves, L.; Diehl, L.; Schaefer, G.; Kapadia, S.B. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J. Virol. 2012, 86, 10935-10949.
91. Karlas, A.; Machuy, N.; Shin, Y.; Pleissner, K.P.; Artarini, A.; Heuer, D.; Becker, D.; Khalil, H.; Ogilvie, L.A.; Hess, S.; et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010, 463, 818-822.
92. Zeisel, M.B.; Lupberger, J.; Fofana, I.; Baumert, T.F. Host-targeting agents for prevention and treatment of chronic hepatitis C-perspectives and challenges. J. Hepatol. 2013, 58, 375-384.
93. Fofana, I.; Xiao, F.; Thumann, C.; Turek, M.; Zona, L.; Tawar, R.G.; Grunert, F.; Thompson, J.; Zeisel, M.B.; Baumert, T.F. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One 2013, 8, e64221.
94. Morikawa, K.; Zhao, Z.; Date, T.; Miyamoto, M.; Murayama, A.; Akazawa, D.; Tanabe, J.; Sone, S.; Wakita, T. The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J. Med. Virol. 2007, 79, 714-723.
95. Meuleman, P.; Hesselgesser, J.; Paulson, M.; Vanwolleghem, T.; Desombere, I.; Reiser, H.; Leroux-Roels, G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008, 48, 1761-1768.
96. VanCompernolle, S.E.; Wiznycia, A.V.; Rush, J.R.; Dhanasekaran, M.; Baures, P.W.; Todd, S.C. Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology 2003, 314, 371-380.
97. Fofana, I.; Krieger, S.E.; Grunert, F.; Glauben, S.; Xiao, F.; Fafi-Kremer, S.; Soulier, E.; Royer, C.; Thumann, C.; Mee, C.J.; et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010, 139, 953-964, 964, e951-e954.
98. Si, Y.; Liu, S.; Liu, X.; Jacobs, J.L.; Cheng, M.; Niu, Y.; Jin, Q.; Wang, T.; Yang, W. A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology 2012, 56, 507-515.
99. Hotzel, I.; Chiang, V.; Diao, J.; Pantua, H.; Maun, H.R.; Kapadia, S.B. Efficient production of antibodies against a mammalian integral membrane protein by phage display. Protein Eng. Des. Sel. 2011, 24, 679-689.
100. Pilot-Matias, T.; Lacy, S.; Ng, T.; Barbon, J.; Fung, E.; Pithawalla, R.; Barlow, E.; Kutskova, Y.; Hsieh, C.-M.; DiGiammarino, E.; et al. Evaluation of a panel of anti-CD81 antibodies using human liver-uPA/SCID mice. In Proceedings of the 17th International Meeting on Hepatitis C Virus and Related Viruses, Yokohama, Japan, 10-14 September 2010.
101. Bardou-Jacquet, E.; Lorho, R.; Guyader, D. Kinase inhibitors in the treatment of chronic hepatitis C virus. Gut 2011, 60, 879-880.
102. Lupberger, J.; Duong, F.H.; Fofana, I.; Zona, L.; Xiao, F.; Thumann, C.; Durand, S.C.; Pessaux, P.; Zeisel, M.B.; Heim, M.H.; Baumert, T.F. EGFR signaling impairs the antiviral activity of interferon-alpha. Hepatology 2013, 58, 1225-1235.
103. Reuther, G.W.; Der, C.J. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell Biol. 2000, 12, 157-165.
104. Kohl, N.E.; Mosser, S.D.; deSolms, S.J.; Giuliani, E.A.; Pompliano, D.L.; Graham, S.L.; Smith, R.L.; Scolnick, E.M.; Oliff, A.; Gibbs, J.B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260, 1934-1937.
105. James, G.L.; Goldstein, J.L.; Brown, M.S.; Rawson, T.E.; Somers, T.C.; McDowell, R.S.; Crowley, C.W.; Lucas, B.K.; Levinson, A.D.; Marsters, J.C., Jr. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 1993, 260, 1937-1942.
106. Marom, M.; Haklai, R.; Ben-Baruch, G.; Marciano, D.; Egozi, Y.; Kloog, Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J. Biol. Chem. 1995, 270, 22263-22270.
107. Sawada, K.; Ohyagi-Hara, C.; Kimura, T.; Morishige, K. Integrin inhibitors as a therapeutic agent for ovarian cancer. J. Oncol. 2012, 2012, 915140.